- Home
- ADXN vs GLTO Comparison
ADXN vs GLTO Comparison
Compare ADXN & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- GLTO
- Stock Information
- Founded
- ADXN 2002
- GLTO 2011
- Country
- ADXN Switzerland
- GLTO Denmark
- Employees
- ADXN N/A
- GLTO N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- GLTO Health Care
- Exchange
- ADXN Nasdaq
- GLTO Nasdaq
- Market Cap
- ADXN 7.5M
- GLTO 6.5M
- IPO Year
- ADXN N/A
- GLTO 2020
- Fundamental
- Price
- ADXN $7.60
- GLTO $2.85
- Analyst Decision
- ADXN Strong Buy
- GLTO Buy
- Analyst Count
- ADXN 1
- GLTO 1
- Target Price
- ADXN $30.00
- GLTO $10.00
- AVG Volume (30 Days)
- ADXN 8.7K
- GLTO 50.5K
- Earning Date
- ADXN 06-05-2025
- GLTO 05-06-2025
- Dividend Yield
- ADXN N/A
- GLTO N/A
- EPS Growth
- ADXN N/A
- GLTO N/A
- EPS
- ADXN 0.06
- GLTO N/A
- Revenue
- ADXN $701,260.00
- GLTO N/A
- Revenue This Year
- ADXN N/A
- GLTO N/A
- Revenue Next Year
- ADXN N/A
- GLTO N/A
- P/E Ratio
- ADXN $0.99
- GLTO N/A
- Revenue Growth
- ADXN N/A
- GLTO N/A
- 52 Week Low
- ADXN $6.51
- GLTO $2.01
- 52 Week High
- ADXN $17.05
- GLTO $18.50
- Technical
- Relative Strength Index (RSI)
- ADXN 52.85
- GLTO 46.24
- Support Level
- ADXN $6.75
- GLTO $2.36
- Resistance Level
- ADXN $8.20
- GLTO $2.86
- Average True Range (ATR)
- ADXN 0.46
- GLTO 0.29
- MACD
- ADXN 0.06
- GLTO 0.09
- Stochastic Oscillator
- ADXN 64.50
- GLTO 98.59
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.